Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Neisseria gonorrhoeae outer membrane antigens represent a complex array of surface-exposed molecules that are primary targets for the host immune system and vaccine development. These antigens include major porins like PorB, which regulates ion flow and host cell apoptosis, and opacity (Opa) proteins that mediate high-affinity adherence to human CEACAM receptors [1][2]. Other critical components include the type IV pili for motility, the MtrE efflux pump for antibiotic resistance, and lipooligosaccharides (LOS) that trigger inflammatory signaling [3]. Because N. gonorrhoeae lacks a capsule, these outer membrane components are the principal interface for host-pathogen interactions and are subject to intense selective pressure, resulting in high levels of antigenic and phase variation [4]. Therapeutic strategies focus on identifying conserved antigens, such as the Neisserial Heparin-Binding Antigen (NHBA), to overcome this variability. Notably, the 4CMenB vaccine has demonstrated significant cross-protective efficacy against gonorrhea in clinical studies by targeting these shared neisserial surface proteins [5]. Monoclonal antibodies like 2C7 are also being developed to target conserved epitopes of the LOS to promote complement-mediated killing [6]. Targeting these antigens aims to induce protective immunity or disrupt essential bacterial processes to combat the rising threat of multi-drug resistant gonorrhea. (Sources: [1] PubMed PMID: 25231120; [2] UniProt P0C0P5; [3] StatPearls - Gonorrhea; [4] Nature Reviews Microbiology, 2014; [5] The Lancet Infectious Diseases, 2022; [6] PubMed PMID: 31631128).
Induction of bactericidal antibodies and opsonophagocytosis; inhibition of host cell attachment and invasion; disruption of membrane-associated transport and resistance mechanisms.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Neisseria gonorrhoeae outer membrane antigens (Ng OMA) (Ng OMA).